The synthetic CD4 exocyclic CDR3.AME(82-89) inhibits NF-κB nuclear translocation, HIV-1 promoter activation, and viral gene expression

DNA and Cell Biology

Volumn 18, Issue 11, 1999, Pages 819-828

  Roland, Joachim ^a,c   Berezov, Alan ^b   Greene, Mark I ^b   Murali, Ramachandran ^b   Piatier Tonneau, Dominique ^a   Devaux, Christian ^a   Briant, Laurence ^a  

^a CNRS   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CNRS UPR420 ^*

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; VIRUS EXPRESSION; VIRUS GENE; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; NF-KAPPA B; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032753729     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454999314818     Document Type: Article

References (52)

1. ADAM, D., KLAGES, S., BISHOP, P., MAHAJAN, S., ESCOBEDO, J.A., and BOLEN, J.B. (1993). Signal transduction through a biomolecular receptor tyrosine protein kinase composed of a platelet-derived growth factor receptor-CD4 chimera and the nonreceptor tyrosine protein kinase Lck. J. Biol. Chem. 268, 19882-19888.
2. ARTHOS, J., DEEN, K.C., CHAIKIN, M.A., FORNWALD, J.A., SATHE, G., SATTENTAU, Q.J., CLAPHAM, P.R., WEISS, R.A., MCDOUGAL, J.S., PIETROPAOLO, C., AXEL, R., TRUNEH, A., MADDON, P.J., and SWEET, R.W. (1989). Identification of the residues in the human CD4 critical for the binding of the HIV. Cell 57, 469-481.
3. BATINIC, D., and ROBEY, F.A. (1992). The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J. Biol. Chem. 267, 6664-6671.
4. BENKIRANE, M., CORBEAU, P., HOUSSET, V., and DEVAUX, C. (1993). An antibody that binds the immunoglobin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells. EMBO J. 12, 4909-4921.
5. BENKIRANE, M., JEANG, K.T., and DEVAUX, C. (1994). The cytoplasmic domain of CD4 plays a critical role during the early stages of HIV infection in T-cells. EMBO J. 13, 5559-5569.
6. BENKIRANE, M., SCHMID-ANTOMARCHI, H., LITTMAN, D.R., HIRN, M., ROSSI, B., and DEVAUX, C. (1995). The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain of CD4. J. Virol. 69, 6904-6910.
7. BRIANT, L., ROBERT-HEBMANN, V., ACQUAVIVA, C., PELCHEN-MATTHEWS, A., MARSH, M., and DEVAUX, C. (1998a). The protein tyrosine kinase p56lck is required for triggering NF-kappa B activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4. J. Virol. 72, 6207-6214.
8. BRIANT, L., ROBERT-HEBMANN, V., SIVAN, V., BRUNET, A., POUYSSEGUR, J., and DEVAUX, C. (1998b). Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling activation of nuclear factor-kappa B and AP-1 transcription factors. J. Immunol. 160, 1875-1885.
9. BRIANT, L., SIGNORET, N., GAUBIN, M., ROBERT-HEBMANN, V., ZHANG, X., MURALI, R., GREENE, M.I., PIATIER-TONNEAU, D., and DEVAUX, C. (1997). Transduction of activation signal that follows HIV-1 binding to CD4 and CD4 dimerization involves the Immunoglobulin CDR3-like region in domain 1 of CD4. J. Biol. Chem. 272, 19441-19450.
10. BRIANT, L., and DEVAUX, C. (1999). Bioactive CD4 ligands as pre and/or post-binding inhibitors of HIV-1. In HIV: Molecular Mechanisms and Clinical Applications. K.T. Jeang, ed. (in press).
11. BRODER, C.C., and BERGER, E.A. (1993). CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion. J. Virol. 67, 913-926.
12. CAMERINI, D., and SEED, B. (1990). A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site. Cell 60, 747-754.
13. 1H NMR spectroscopy and molecular modelng: Relevance of conformation to biological function. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11, 222-232.
14. CHARDES, T., VILLARD, S., FERRIERES, G., PIECHACZYK, M., CERUTTI, M., DEVAUCHELLE, G., and PAU, B. (1999). Efficient amplification and direct sequencing of mouse variable regions from any immunoglobulin gene family. FEBS Lett. 452, 386-394.
15. CLAYTON, L.K., SIEH, M., PIOUS, D.A., and REINHERZ, E.L. (1989). Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. Nature 339, 548-551.
16. CORBEAU, P., BENKIRANE, M., WEIL, R., DAVID, C., EMILIANI, S., OLIVE, D., MAWAS, C., SERRE, A., and DEVAUX, C. (1993). Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncitia formation but not in viral entry. J. Immunol. 150, 290-301.
17. COUDRONNIERE, N., and DEVAUX, C. (1998). A novel complex of proteins binds the HIV-1 promoter upon virus interaction with CD4. J. Biomed. Sci. 5, 281-289.
18. CRUIKSHANK, W.W., LIM, K., THEODORE, A.C., COOK, J., FINE, G., WELLER, P.P., and CENTER, D.M. (1996). IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J. Immunol. 157, 5240-5248.
19. DOUGALL, W.C., PETERSON, N.C., and GREENE, M.I. (1994). Antibody-structure-based design of pharmacological agents. Trends Biotechnol. 12, 372-379.
20. DOYLE, C., and STOMINGER, J.L. (1987). Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330, 256-259.
21. GUILLERM, C., ROBERT-HEBMANN, V., HIBNER, U., HIRN, M., and DEVAUX, C. (1998). An anti-CD4 (CDR3-loop) monoclonal antibody inhibits human immunodeficiency virus type 1 envelope glycoprotein-induced apoptosis. Virology 248, 254-263.
22. JABADO, N., DEIST, F.L., FISCHER, A., and HIVROZ, C. (1994). Interaction of HIV gp120 and ami CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the binding activity of NF-AT, NF-κB and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity. Eur. J. Immunol. 24, 2646-2652.
23. JAMESON, B.A., MCDONNELL, J.M., MARINI, J.C., and KORNGOLD, R. (1994). A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 368, 744-746.
24. KOCH, U., CHOKSI, S., MARCUCCI, L., and KORNGOLD, R. (1998). A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier. J. Immunol. 161, 421-429.
25. KRUISBEEK, A.M., MOND, J.J., FOWLKES, B.J., CARMEN, J.A., BRIDGES, S., and LONGO, D.L. (1985). Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. J. Exp. Med. 161, 1029-1047.
26. LAMARRE, D., CAPON, D.J., KARP, D.R., GREGORY, T., LONG, E.O., and SEKALY, R.P. (1989). Class II MHC molecules and the HIV gp 120 envelope protein interact with functionally distinct regions of the CD4 molecule. EMBO J. 8, 3271-3277.
27. LANGEDIJK, J.P.M., PUIJK, W.C., VAN HOORN, W.P., and MELOEN, R.H. (1993). Location of CD4 dimerization site explains critical role of the CDR3-like region in HIV-1 infection and T-cell activation and implies a model for complex of coreceptor-MCH. J. Biol. Chem. 268, 16875-16878.
28. LASARTE, J.J., SAROBE, P., GOLVANO, J., PRIETO, I. CIVEIRA, M.P., GULLON, A., SARIN, P.S., PRIETO, J., and BORRASCUESTA, F. (1994). CD4-modified synthetic peptides containing phenylalanine inhibit HIV-1 infection in vitro. J. Acquir. Immune Defic. Syndr. 7, 129-134.
29. lck negative HTLV-I transformed cell line. J. Immunol. 156, 859-865.
30. LEMASSON, I., HOUSSET, V., CALAS, B., and DEVAUX, C. (1995). Antigenic analysis of HIV type 1 external envelope (Env) glycoprotein C2 region: Implication for the structure of Env. AIDS Res. Hum. Retrovir. 11, 1177-1186.
31. LI, S., GAO, J., SATOH, T., FRIEDMAN, T.M., EDLING, A.E., KOCH, U., CHOKSI, S., HAN, X., KORNGOLD, R., and HUANG, Z. (1997). A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics. Proc. Natl. Acad. Sci. USA 94, 73-78.
32. LI, S., SATOH, T., KORNGOLD, R., and HUANG, Z. (1998). CD4 dimerization and oligomerization: Implications for T-cell function and structure-based drug design. Immunol. Today 19, 455-462.
33. LIFSON, J.D., HWANG, K.M., NARA, P.L., FRASER, B., PADGETT, M., DUNLOP, N.M., and EIDEN, L.E. (1988). Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 241, 712-716.
34. MADDON, P.J., DALGLEISH, A.C., MCDOUGAL, J.S., CLAPHAM, P.R., WEISS, R.A., and AXEL, R. (1986). The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333-348.
35. + T cell responses in experimental allergic encephalomyelitis. J. Immunol. 157, 3706-3715.
36. MCDONNELL, J.M., BLANK, K.J., RAO, P.E., and JAMESON, B.A. (1992). Direct involvement of the CDR3-like domain of CD4 in T helper cell activation. J. Immunol. 149, 1626-1630.
37. MITZUKAMI, T., FUEST, T.R., BERGER, E.A., and MOSS, B. (1988). Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 85, 9273-9277.
38. MONNET, C., LAUNE, D., LAROCHE-TRAINEAU, J., BIARDPIECHACZYK, M., BRJANT, L., BES, C., PUGNIERE, M., MANI, J.C., PAU, B., CERUTTI, M., DEVAUCHELLE, G., DEVAUX, C., GRANIER, C., and CHARDES, T. (1999). Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. J. Biol. Chem. 274, 3789-3796.
39. MOUTOUH, L., ESTAQUIER, J., RICHMAN, D.D., and CORBEIL, J. (1998). Molecular and cellular analysis of human immunodeficiency virus-induced apoptosis in lymphoblastoid T-cell-line expressing wild-type and mutated CD4 receptors. J. Virol. 72, 8061-8072.
40. NARA, P.L., HWANG, K.M., RAUSCH, D.M., LIFSON, J.D., and EIDEN, L.E. (1989). CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. Proc. Natl. Acad. Sci. USA 86, 7139-7143.
41. OHKI, K., KIMURA, T., OHMURA, K., KATO, S., and IKUTA, K. (1990). Blocking of HIV-1 infection, but not HIV-1-induced syncytium formation, by a CD4 peptide derivative partly corresponding to an immunoglobulin CDR3. AIDS 4, 1160-1161.
42. OHKI, K., KIMURA, T., OHMURA, K., MORIKAWA, Y., JONES, I.M., AZUMA, I., and IKUTA, K. (1992). Monoclonal antibodies to a CD4 peptide derivative which includes the region corresponding to an immunoglobulin CDR3: evidence of the involvement of pre-CDR3-related region in HIV-1 and host cell interaction. Mol. Immunol. 29, 1391-1400.
43. RAUSCH, D.M., HWANG, K.M., PADGETT, M., VOLTZ, A.H., RIVAS, A., ENGLEMAN, E., GASTON, I., MCGRATH, M., FRASER, B., KALYANARAMAN, V.S., NARA, P.L., DUNLOP, N., MARTIN, L., MURPHEY-CORB, M., KIBORT, T., LIFSON, J.D., and EIDEN, L.E. (1990). Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HFV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro: implications for the design of small peptide anti-HIV therapeutic agents. Ann. N.Y. Acad. Sci. 616, 125-148.
44. REPKE, H., GABUZDA, D., PALU, G., EMMRICH, F., and SODROSKI, J. (1992). Effects of CD4 synthetic peptides on HIV type I envelope glycoprotein function. J. Immunol. 149, 1809-1816.
45. REY, M.A., SPIRE, B., DORMONT, D., BARRE-SINOUSSI, F., MONTAGNIER, L., and CHERMANN, J.C. (1984). Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus). Biochem. Biophys. Res. Commun. 121, 126-133.
46. RYU, S.E., KWONG, P.D., TRUNEH, A., PORTER, T.G., ARTHOS, J., ROSENBERG, M., DAI, X.P., XUONG, N.H., AXEL, R., SWEET, R.W., and HENDRICKSON, W.A. (1990). Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature 348, 419-426.
47. SAKIHAMA, T., SMOLYAR, A., anD REINHERZ, E.L. (1995). Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc. Natl. Acad. Sci. USA 92, 6444-6448.
48. WANG, J.H., YAN, Y.W., GARRETT, T.P., LIU, J.H., RODGERS, D.W., GARLICK, R.L., TARR, G.E., HUSAIN, Y., REINHERZ, E.L., and HARRISON, S.C. (1990). Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature 348, 411-418.
49. WANG, J.M., UEDA, H., HOWARD, O.M., GRIMM, M.C., CHERTOV, O., GONG, X., GONG, W., RESAU, J.H., BRODER, C.C., EVANS, G., ARTHUR, L.O., RUSCETTI, F.W., and OPPENHEIM, J.J. (1998). HIV-1 envelope gp120 inhibits the monocyte response to chemokines through CD4 signal-dependent chemokine receptor down-regulation. J. Immunol. 161, 4309-4317.
50. WU, H., KWONG, P.D., and HENDRICKSON, W.A. (1997). Dimeric association and segmental variability in the structure of human CD4. Nature 387, 527-530.
51. ZHANG, X., GAUBIN, M., BRIANT, L., SRIKANTAN, V., MURALI, R., SARAGOVI, U., WEINER, D., DEVAUX, C., AUTIERO, M., PIATIER-TONNEAU, D., and GREENE, M.I. (1997). Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nature Biotech. 15, 150-154.
52. ZHANG, X., PIATIER-TONNEAU, D., MURALI, R., MAHAPATRA, A., ZHANG, F., MAIER, C.C., SARAGOVI, H., and GREENE, M.I. (1996). Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nature Biotech. 14, 472-475.